Rabies immune globulin, human
Identification
- Summary
Rabies immune globulin, human is a solution of antibodies used to prevent rabies after an exposure.
- Brand Names
- Hyperrab, Imogam, Kedrab, Rabavert
- Generic Name
- Rabies immune globulin, human
- DrugBank Accession Number
- DB11603
- Background
IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.
Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine.
IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.
Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Polyclonal antibody (pAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Human rabies virus immune globulin
- Rabies immune globulin
- Rabies immune globulin (human)
- Rabies immune globulin human
- Rabies immune globulin,human
- Rabies immunoglobulin (human)
- Rabies immunoglobulins
Pharmacology
- Indication
For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine [FDA Label].
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Rabies immune globulin prevents viral invasion of the central nervous system.
- Mechanism of action
Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system [FDA Label]. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.
Target Actions Organism ARabies Virus Proteins antibodyRabies virus (strain Pasteur vaccins / PV) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted [FDA Label].
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Hyperab Rabies Immune Globulin Human Liquid Intramuscular Cutter Med & Biol, Division Of Miles Canada Ltd. 1985-12-31 1998-09-25 Canada 
HyperRAB Injection, solution 300 [iU]/1mL Infiltration; Intramuscular GRIFOLS USA, LLC 1974-06-12 Not applicable US 
HyperRAB Solution 300 unit Intramuscular Grifols Therapeutics Llc 2019-07-02 Not applicable Canada Hyperrab S/d Solution Intramuscular Grifols Therapeutics Llc 1997-10-09 Not applicable Canada Hyperrab S/d Injection 150 [iU]/1mL Intramuscular GRIFOLS USA, LLC 1996-08-14 Not applicable US Imogam Rabies Inj 150unit/ml Liquid Intramuscular Pasteur mÉrieux Serums Et Vaccins, s.a. 1991-12-31 1999-08-12 Canada Imogam Rabies Pasteurized Solution Intramuscular Sanofi Pasteur Limited 1999-04-30 Not applicable Canada Imogam Rabies-HT Injection, solution 150 [iU]/1mL Intramuscular Sanofi Pasteur Inc. 1984-04-27 Not applicable US Kamrab Solution Intramuscular Kamada Ltd Not applicable Not applicable Canada Kamrab Solution Intramuscular Kamada Ltd 2020-04-06 Not applicable Canada
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 95F619ATQ2
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- AHFS Codes
- 80:04.00 — Serums
- 80:12.00 — Vaccines
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Rabies 2 4 Recruiting Treatment Primary Immune Deficiency (PID) 1 4 Withdrawn Prevention Virus Diseases 1 3 Active Not Recruiting Prevention Rabies (Healthy Volunteers) 1 3 Active Not Recruiting Prevention Virus Diseases 1 3 Completed Prevention Children, Only / Malaria caused by Plasmodium falciparum 1 3 Completed Prevention Plasmodium Infections 1 3 Completed Prevention Rabies Infection 1 3 Completed Prevention Rabies Prevention 1 3 Recruiting Prevention Rabies (Healthy Volunteers) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular Solution Intramuscular; Subcutaneous Injection, solution Infiltration; Intramuscular 300 [iU]/1mL Solution Intramuscular 300 unit Injection Intramuscular 150 [iU]/1mL Liquid Intramuscular Solution Intramuscular Injection, solution Intramuscular 150 [iU]/1mL Powder, for solution Intramuscular 2.5 IU/mL Injection, powder, for solution Intramuscular Solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
- Kind
- Protein group
- Organism
- Rabies virus (strain Pasteur vaccins / PV)
- Pharmacological action
- Yes
- Actions
- Antibody
- General Function
- Attaches the virus to host cellular receptor, inducing endocytosis of the virion. In the endosome, the acidic pH induces conformational changes in the glycoprotein trimer, which trigger fusion between virus and cell membrane. There is convincing in vitro evidence that the muscular form of the nicotinic acetylcholine receptor (nAChR), the neuronal cell adhesion molecule (NCAM), and the p75 neurotrophin receptor (p75NTR) bind glycoprotein and thereby facilitate rabies virus entry into cells (By similarity).
- Specific Function
- Not Available
Components:
| Name | UniProt ID |
|---|---|
| Glycoprotein | P08667 |
| Large structural protein | P11213 |
| Matrix protein | P08671 |
| Nucleoprotein | P06025 |
| Phosphoprotein | P06747 |
References
- Sikes RK: Human rabies immune globulin. Public Health Rep. 1969 Sep;84(9):797-801. [PubMed:4185138]
- Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, Kuzmin IV, Marissen WE, Rupprecht CE: In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3). pii: tropicalmed2030048. doi: 10.3390/tropicalmed2030048. [PubMed:30270905]
Drug created on June 01, 2016 20:49 / Updated on May 06, 2021 06:19